Urology Testing
Results urologists can trust
Our team of urologic pathologists provides academic-caliber, definitive diagnoses. Our pathologists utilize advanced, in-house testing, including comprehensive Immunohistochemistry (IHC) panels, to supplement morphological evaluations of difficult cases. We also offer send-out testing options including Prolaris®, Decipher, and Confirm MDX for clinicians who request it. Inform Diagnostics believes in responsible test utilization and only orders tests that are medically appropriate for accurate diagnosis.
Urology Test Offerings
Definitive diagnoses using advanced urologic testing
Our offerings for urology testing give clinicians timely, definitive answers. Our uropathologists are always available to answer clinicians’ questions so they can recommend treatment with confidence.
| Test Offering | Test Details | Category | Indications |
|---|---|---|---|
| Prostate biopsy evaluation | Prostate biopsy evaluation, prostate cancer nomograms (Partin and Han tables) | Prostate | Prostate cancer detention |
| PIN-ERG | Multiplex ERG, basal cell markers, and AMACR IHC | Prostate | To improve prostate cancer detection and resolve atypical diagnosis in prostate biopsies |
| PINgenius™ | Following diagnosis of HGPIN, uses biomarker overexpression as well as several histological factors | Prostate | To predict the risk of prostate cancer at re-biopsy |
| Bladder biopsies | Mucosal cup biopsies and transurethral resection of bladder tumor | Bladder | Bladder cancer detection |
| Tumor of uncertain origin | A panel of NKX3.1, PSA, PSMA, ERG, GATA3, p63, HMWCK IHC markers | Prostate and bladder | |
| Urothelial dysplasia panel | A panel of CK20, Ki-67, P53 and CD44 IHC | Bladder | Differentiation of urothelial dysplasia/CIS from reactive and therapy atypia |
| Urine/bladder and renal pelvic wash cytology | Cytomophologic analysis of urothelial cells | Bladder | Bladder cancer detection |
| UroVysion test | FISH measurement of chromosome 3,7,17 and loss of 9p in urothelial cells secreted in urine | Bladder | To improve bladder cancer detection complementing urine cytology |
| Testis biopsy | Histological analysis of testis biopsy | Testis | Infertility evaluation |
| Testis tumor evaluation | Complete evaluation of tumor with utilization of germ cell markers IHC when applicable | Testis | Evaluation of a mass lesion |
| Stone evaluation | Chemical analysis of stone | Kidney, bladder | To determine chemical composition of stone |
| Renal mass biopsy evaluation | Classification of renal tumor in biopsy with application of select tumor markers panel | Kidney | To aid in treatment decision for renal mass management |
| Skin biopsy and resections | Evaluation of skin lesions affecting penis/scrotum and perineal area | Penis, scrotum | Evaluation of a skin lesion or mass |
| HPV genotype | In situ hybridization studies of low and high-risk HPV | Penis, scrotum | To determine HPV risk potential |
